pegunigalsidase alfa: clinical use

Prescribing considerations

• Confirm Fabry disease and manage treatment through a physician experienced in the condition.
• Ensure appropriate medical support is available, particularly for treatment-naive patients or those with previous severe hypersensitivity.
• Consider antihistamine or corticosteroid premedication following previous hypersensitivity reactions.
• Record the product name and batch number for biological-medicine traceability.
• Assess suitability, stability, training and emergency arrangements before home infusion.

Contraindications and cautions

• Hypersensitivity to pegunigalsidase alfa or any excipient.
• Use particular caution if rechallenging after severe hypersensitivity.
• Anti-drug antibodies may increase the risk and severity of infusion reactions.
• Extensive established renal damage may limit renal response.
• Consider total sodium exposure where clinically relevant.

Monitoring

• Observe for infusion-related and hypersensitivity reactions during and after administration.
• Monitor renal function and proteinuria regularly.
• Assess Fabry disease status using appropriate renal, cardiac, biochemical and lyso-Gb3 measures.
• Consider anti-drug antibody assessment where infusion or immune reactions occur or clinical effect appears reduced.

Clinical pharmacology

Pegunigalsidase alfa is a PEG-conjugated recombinant human alpha-galactosidase A produced in plant cells. It supplements lysosomal enzyme activity and reduces cellular accumulation of Gb3 and lyso-Gb3; as a protein, it is expected to undergo peptide hydrolysis rather than cytochrome P450 metabolism.

Formulation and product differences

• Clear, colourless concentrate supplied in two single-use vial sizes at the same concentration.
• The larger vial contains more sodium than the smaller vial.
• Requires dilution in sodium chloride solution and administration through an in-line low-protein-binding filter.
• Do not mix with other medicinal products or infuse through the same intravenous line.

Solution for infusion

Route: Intravenous

Strengths: 2 mg/mL